Drug Trial Radar · NCT05171049
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,150
Actual
Start
May 5, 2022
Primary completion
Feb 4, 2026
Study completion Feb 4, 2026
Sponsor
- Lead sponsor
- Anthos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Dec 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Conditions
- Venous Thromboembolism
- Deep Venous Thrombosis
- Pulmonary Embolism
Interventions
AbelacimabBiological
Abelacimab 150 mg
ApixabanDrug
Apixaban 10 mg followed by 5 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first event of centrally adjudicated VTE recurrenceTime frame: Up to 6 months
Locations
209 sites in 21 countries. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus
Aurora, Colorado
VA Connecticut Healthcare System
West Haven, Connecticut
Washington DC VAMC
Washington D.C., District of Columbia
University of Miami Health
Miami, Florida
NorthShore University Health System
Evanston, Illinois
University of Kentucky, Markey Cancer Center
Lexington, Kentucky
Brigham and Women's Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Washington University
St Louis, Missouri
Memorial Sloan Kettering Cancer Center-Middletown
Middletown, New Jersey
Memorial Sloan Kettering Cancer Center-Commack
Commack, New York
Memorial Sloan Kettering Cancer Center-West Harrison
Harrison, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Lipson Cancer Institute
Rochester, New York
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
University of Pennsylvania - Penn Blood Disorders Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
University of Texas Mays Cancer Center
San Antonio, Texas
Gundersen Health System
La Crosse, Wisconsin
Blood Center of Wisconsin
Milwaukee, Wisconsin
Perth Blood Institute
Perth, Australia
The Alfred Hospital
Prahran, Australia
Blacktown Hospital
Blacktown, New South Wales, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre Clayton
Clayton, Victoria, Australia
Northern Health
Epping, Victoria, Australia
LKH - Universitätsklinikum Graz
Graz, Austria
LK Wiener Neustadt
Neustadt, Austria
Medical University of Vienna
Vienna, Austria
Queen Elizabeth II Health Sciences Centre
Nova Scotia, Canada
McGill University Health Centre
Québec, Canada
University of Calgary
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Hamilton Health Sciences, Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada
Ottawa Hospital
Ottawa, Ontario, Canada
Showing 40 of 209 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.